Top Medical News
an hour ago
Sodium-glucose co-transporter type 2 (SGLT2) inhibitors do not appear to induce an increased rate of venous thromboembolism in patients with type 2 diabetes as compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, which provides reassurance in terms of the thromboembolic safety of the former, according to a recent study.
Jairia Dela Cruz, 22 hours ago
Population-wide policies to lower the amount of salt people consume may considerably cut the incidence of cardiovascular disease (CVD) in Singapore, as reported in a recent study.
Pearl Toh, Yesterday
Undergoing a structured weight loss programme after ablation for atrial fibrillation (AF) does not confer significant reduction in AF burden compared with usual care, according to the SORT-AF* study presented at EHRA 2021.
3 days ago
Use of dual-release hydrocortisone in the treatment of patients with adrenal insufficiency appears to confer extended benefits, such as that for cognitive function and quality of sleep, a study has found.
6 days ago
Exposure to air pollution in early life appears to contribute to a small increase in the risk of developing overweight or obesity in childhood, with the association more pronounced among children in the most deprived areas, as reported in a study.
6 days ago
Even among patients with diabetes mellitus (DM) but no diabetic retinopathy (NDR), thinning of the retinal neuronal and axonal layers is apparent, a recent meta-analysis has found. In turn, this suggests that DR neuropathy (DRN) may be an early marker of clinically detectable DR.
06 May 2021
Some patients receiving chemotherapy with dexamethasone develop diabetes, and this risk is especially prominent in men and in the presence of impaired fasting glucose, according to a study.
Special Reports
06 May 2021
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

26 Oct 2020

An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]

Pank Jit Sin, 02 Sep 2020
The most recent report by the National Health and Morbidity Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with consistent, unrelenting efforts by stakeholders and policymakers, the figures for NCDs continue to climb. MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in the country and to obtain his thoughts on the ramifications of the findings. 
11 Aug 2020
In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.
Conference Reports
Elaine Soliven, 27 Apr 2021
Weekly (QW) or biweekly (Q2W) treatment with BIO89-100 led to a significantly reduced liver fat and liver fat volume (LFV) in patients with nonalcoholic steatohepatitis (NASH), according to a recent study presented at ENDO 2021.
Roshini Claire Anthony, 23 Apr 2021

Ertugliflozin may be a suitable add-on therapy in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) whose glucose levels are inadequately controlled by a metformin-sulfonylurea or insulin regimen, substudies of the phase III VERTIS* CV trial showed.

Elaine Soliven, 22 Apr 2021
Adults who took their first meal before 8:30 am had better insulin resistance than those who did so after 8:30 am, independent of eating duration, according to a study presented at ENDO 2021.
Elvira Manzano, 15 Apr 2021
New evidence from a recent trial points to a genetically defined male equivalent of PCOS* that is characterized by ovarian-independent pathogenesis and can increase risks for excess weight, type 2 diabetes (T2D), and cardiovascular disease (CVD) in men, reports an expert at ENDO 2021.
Tristan Manalac, 15 Apr 2021
Patients and healthcare practitioners in the endocrinology setting seem satisfied with the use of telemedicine, and most say that they would want to maintain such a system even after the novel coronavirus disease (COVID-19) pandemic, according to a study presented at the recently concluded ENDO 2021 virtual conference by the Endocrine Society.
Roshini Claire Anthony, 14 Apr 2021

In patients hospitalized with COVID-19, hypernatraemia during hospitalization may increase mortality risk, while hyponatraemia at admission may up the need for ventilation support, a recent study from the UK showed.

Jairia Dela Cruz, 14 Apr 2021
Administering recombinant human insulin-like growth hormone-1 (rhIGF-1) for 6 months followed by risedronate for another 6 months helps improve bone mineral density (BMD) at the spine in women with anorexia nervosa, according to a study.